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 
Abstract— Extending safe, effective glycemic control to the 
general wards requires a simple approach using subcutaneous 
(SC) insulin. However, this approach can increase relative risk 
compared to intravenous insulin due to the increased 
variability of SC insulin appearance. This paper evaluates the 
accuracy of a SC plasma insulin model and optimizes its 
parameters using measured plasma insulin data from 6 less 
acute critical care patients treated with SC insulin. The SC 
plasma insulin model used captures the dynamics of regular SC 
insulin well. However, there appears to be a positive bias 
leading to an overall median [IQR] residual error of -28.3 [-37 -
19] mU/L. The optimized model reduced the RMS residual 
error by 20-70% for each patient. The distinct inter- and intra- 
patient, and cohort variation seen in this data highlights the 
importance to of understanding how SC insulin appearance 
dynamics may be affected by the subject condition.  
I. INTRODUCTION 
Stress-induced hyperglycaemia is prevalent in critical care, 
and can occur in patients with no history of diabetes [1-4]. 
Hyperglycaemia worsens outcomes, leading to further risk 
of complications, including sepsis [5], myocardial infarction 
[1], polyneuropathy, and multiple organ failure [2]. Adaptive 
model-based protocols for accurate glycaemic control 
(AGC) that modulate insulin and nutrition have shown 
considerable promise in the intensive care unit (ICU) [6-10]. 
However, they are not suitable for less acute wards because 
of the demands they place on clinical staff [11-14] and the 
lack of intravenous (IV) lines for IV delivery.   
To extend safe, effective glycaemic control to the general 
wards, a simple approach using subcutaneous (SC) insulin 
delivery is necessary. However, there is an increased rick 
when using SC insulin as its appearance is much more 
variable than IV insulin appearance [15]. This increased 
variability compounds the existing difficulty of managing 
intra- and inter- patient variability.  
In model-based control, plasma insulin dynamics have a 
significant impact of identified model parameters, such as 
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insulin sensitivity (SI). Hence, reducing error in modelling 
plasma insulin appearance will reduce SI variability and 
error, and thus increase the accuracy and utility of the 
parameter for glycaemic control.  
This paper evaluates the accuracy of a SC plasma insulin 
model and optimises model parameters for less acute critical 
care patients. Plasma insulin blood samples from an ongoing 
study of SC insulin delivery, in the Christchurch Hospital 
Intensive Care Unit (ICU) were used to evaluate this model.  
II. PATIENTS AND METHODS 
A. Subcutaneous Insulin Study Patients  
A total of 6 patients enrolled in a prospective clinical trial 
studying a protocol for SC insulin delivery. Each patient had 
a set of blood samples assayed for insulin and C-peptide. 
Patients were included in the study if they were:  
 Age ≥ 18 years  
 Expected to survive ICU care 
 Expected ICU length of stay ≥ 72hrs 
 Receiving treatment by the tablet-based STAR AGC 
protocol (Stochastic TARgeted) (2 sequential BG 
measurements ≥ 8mmol/L) [16] 
 In a stable condition, likely to be discharged to less 
acute wards <48hrs  
 
TABLE I.   SUMMARY OF SUBCUTANEOUS TRIAL PATIENT CHARACTERISTICS. 
DATA ARE SHOW AS MEDIAN [IQR] WHERE APPROPRIATE. 
 
Number (N) 6 
Age (years) 58 [43-60] 
Gender (M/F) 5/1 
APACHE II score  18.5 [14.3-23.5] 
Hospital mortality (L/D) (6/0) 
 
Patients received 3 doses of SC insulin over 12 hours. Blood 
glucose (BG) was measured every 30 mins with a blood gas 
analyser (BGA, Radiometer ABL90Flex, Copenhagen). 
Insulin and nutrition doses were determined every 4 hours 
by an SC insulin protocol. This study was approved by the 
Upper South Regional Ethics Committee, New Zealand.  
During each 12 hour trial, 18 blood samples were taken to 
assess plasma insulin concentrations. Samples were taken at 
times t = 0, 30, 60, 90, 180, 240mins where t = 0 mins  marks 
the first SC insulin bolus given. Insulin   concentrations were 
determined using immunometric assays (Elecsys 2010, 
Roche Diagnostics, Germany).  The reported coefficient of 
variation (CVA) for the insulin 3.8% [17, 18]. 
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B. Model   
For this study, the clinically validated Intensive Control 
Insulin-Nutrition-Glucose (ICING) model of the glucose-
insulin system was used [19]. For forward simulation using 
regular SC insulin (e.g. Actrapid, Novo Nordisk, Denmark), 
an additional kinetics sub-model was added, modelling 
transport from the SC layer to the plasma[20]. 
 
    Equation (1) 
 
         Equation (2) 
 
              Equation (3) 
 
                     Equation (4) 
 
Where xh,  are the total insulin mass in the 
hexameric (h), local interstitial, (i), and dimeric or 
monomeric, (dm), compartments, respectively [mU]. 
Transport parameters are denoted  and  [min-1], and 
Udm and Uh are the exogenous appearance rate [mUmin-1] as 
delivered by injection to the dimeric or monomeric and the 
hexameric compartment respectively. pd is the hexameric 
dissociation rate [min-1]. Exogenous insulin input is URI 
[mU.min−1], where the unique scaling factor, fRI, highlights 
the many currently unquantified processes at work during 
the absorption process. The parameters in Table II were 
identified using published clinical data to describe a typical 
plasma insulin profile for regular insulin [21]. The overall 
model describes the appearance a common of SC insulin 
type e.g. Actrapid (Novo Nordisk, Denmark). 
 
TABLE II.   FITTED VALUES OF SUBCUTANEOUS INSULIN MODEL 
CONSTANTS 
 
Parameter  Value 
 
 4.60 x 10
-2 min-1 
 
 1.20 x 10
-2 min-1 
 






C. Analysis Methods  
Measured and modelled plasma insulin values were 
compared and residuals calculated: 
 
Residual Error =I(t)measured – I(t)modelled           Equation (5) 
 
where I(t)measured is the plasma insulin measured during the 
12 hour trials and I(t)modelled is the forward prediction of the 
plasma insulin using the model identified SI profile for these 
patients during the 12 hour trials. Residuals were first 
calculated using the model parameters outlined above. The 
root mean square (RMS) and the median and interquartile 
range (IQR) of the residual errors was calculated for each 
patient and the overall cohort.  Finally, an optimal value of 
the parameter, fRI was identified by iteratively searching the 
range of 0.60 to 0.20 in steps of 0.01 to find the value of fRI 
that generated the smallest residuals and the best model fit.    
 
III. RESULTS AND DISCUSSION 
A. SC Plasma Insulin Model  
The SC plasma insulin model as published by Fisk [20] 
with fRI = 0.597 captures the dynamics of the regular SC 
insulin used in this study well, as seen in Figure I. This 
result indicates the underlying model structure for regular 
insulin is correct. However, there appears to be a positive 
bias leading to an overall median [IQR] residual error of -
28.3 [-37 -19] mU/L. All 6 patients demonstrated this bias 
with the modelled insulin being consistently higher than the 
measured insulin as seen in Table III.  
 
 The updated parameter of fRI = 0.25 significantly reduced 
the residual error with an overall RMS of 17.4 and median 
[IQR] of -5.37 [-15 9.7] mU/L. This value also eliminated 
model bias with 3 patients having a positive median residual 
and 3 patients have a negative median residual, resulting in a 
better overall model fit. RMS residual error was reduced by 
between 20% and 70% for each patient with this adjustment.  
 
The original model value for fRI was found using data from 
18 heathy male volunteers [20]. This change in fRI thus 
reflects a distinct difference in SC insulin kinetics between 
healthy volunteers and critical care patients. This parameter 
is equivalent to a unique clearance in the local interstitium. It 
lumps together difficult to quantify dynamics, such as 
clearance from the subcutaneous depot, affinity to antibodies 
(appearing as different volumes of distribution), and altered 
clearance routes.  Therefore, the reduction of fRI suggests 
less of the injected SC insulin is appearing in critical care 
patients than would appear in a healthy individuals injected 
with the same SC insulin bolus.  
 
This increased degradation of insulin in the local interstitium 
is likely to be due to the increased edema typical of critical 
care patients. The extra fluid at the injection site would slow 
the transport of insulin to the plasma, as well as allowing 
more insulin to be cleared via other pathways.  In addition, 
  
the lack of movement and low skin temperatures found in 
the critically ill have been shown to slow the transport of 
insulin to the plasma [15, 22]. The air temperature in the 
Christchurch ICU is a constant 16 degrees Celsius, and most 
patients are immobilized and only wearing hospital gowns, 
both of which are typical in this setting.   
 
Patient condition also affects the glucose-insulin metabolism 
resulting in inter- and intra- patient variability as condition 
evolves [23]. This impact is evident in Figure I, where there 
are a wide range of plasma insulin response curves. For 
example, Patient 6 shows an acute spike in plasma insulin 
after the 3rd bolus while Patient 5 shows slow insulin plasma 
clearance resulting in plasma insulin concentration building 
up over time.  
 
TABLE III.  RESIDUAL ERROR OF SC MEASURED – MODELLED PLASMA 
INSULIN. DATA PRESENTED AS MEDIAN[IQR].  
Residual 
Error 
fRI = 0.597 fRI = 0.25 
RMS Median[IQR] RMS Median[IQR] 
Patient 
1 
31.3 -31.6 [-36 -26] 8.90 0.144 [-4.9 7.8] 
Patient 
2 
36.2 -36.5 [-44 -29] 21.7 -24.2 [-28 -12] 
Patient 
3 
26.6 -17.8 [-35 -11] 13.0 10.6 [3.9 15] 
Patient 
4 
24.9 -23.6 [-27 -19] 12.1 4.26 [-12 10] 
Patient 
5 
31.1 -22.8 [-33 -9.9] 24.8 -7.58 [-14 25] 
Patient 
6 
34.9 -30.8 [-38 -22] 18.5 -13.0 [-23 -8.0] 




Hence to extend safe, effective glycemic control to the 
general wards, a simple approach using subcutaneous (SC) 
insulin delivery and a simple, generalizable SC insulin 
kinetic transport model are necessary. Such a model must 
also have the ability to account a range of patient conditions. 
The ability to separately account for the variability of SC 
insulin kinetics would enable similar, proven models and 
methods used for AGC in critical care with IV insulin 
delivery to be used for SC insulin delivery, with the addition 
of an SC insulin model that meets these criteria. 
 
To achieve this latter outcome, fRI needs to be optimized 
over large range of patient data instead of having patient 
specific insulin clearance parameters. Variability can also be 
managed through conservative insulin dosing and robust 
protocols. However, the distinct inter-cohort variation seen 
in this data highlights the importance to of understanding 
how the SC dynamics may be affected by the cohort, and 
accounting for them directly. In addition, SC insulin models 
based on healthy, T2DM or critical care data should only be 
cautiously applied to different cohorts.  
 




























































































































































































FIGURE I.  MEASURED AND MODELLED PLASMA INSULIN DATA FOR 









To extend safe, effective glycemic control to the general 
wards, a simple approach using subcutaneous (SC) insulin 
delivery is necessary. However, these changes increase the 
risk due to variability of the patient and the variability that 
can occur in SC insulin appearance [15]. The SC plasma 
insulin model evaluated captures the dynamics of the regular 
SC insulin well. However, there appears to be a positive bias 
leading to an overall median [IQR] residual error of -28.3 [-
37 -19] mU/L. The optimized model reduced the RMS 
residual error by between 20% and 70% for each patient. 
The distinct inter- and intra- patient and cohort variation 
seen in this data highlights the importance of understanding 
how SC dynamics may be affected by the subject condition, 
and accounting for this variability directly in the SC model 
to better generalize existing proven metabolic models used 
in critical care environments. 
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